University of Connecticut

OpenCommons@UConn
Doctoral Dissertations

University of Connecticut Graduate School

3-16-2017

HIV-related Stigma and Health among People
Living with HIV in Middle Georgia: Examining the
Roles of Stress and Coping
Kaylee Burnham
University of Connecticut, kaylee.burnham@uconn.edu

Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Burnham, Kaylee, "HIV-related Stigma and Health among People Living with HIV in Middle Georgia: Examining the Roles of Stress
and Coping" (2017). Doctoral Dissertations. 1497.
https://opencommons.uconn.edu/dissertations/1497

HIV-related Stigma and Health among People Living with HIV in Middle Georgia:
Examining the Roles of Stress and Coping
Kaylee E. Burnham, Ph.D.
University of Connecticut, 2017
Objective – HIV-related stigma and discrimination are drivers of health disparities
among people living with HIV (PLWH). The U.S. South bears much of the burden of the
domestic HIV epidemic. This study seeks to explore the dynamic effects of HIV-related
stigma on health outcomes in a population of PLWH in middle Georgia. Experiences of
enacted HIV stigma in the past year were assessed and participants indicated how
stressful these events were and how they coped with the most impactful event. The
primary study aim tested a moderated serial mediation model of HIV stigma on health in
this population.
Method – A total of 199 people living with HIV completed surveys via audio computerassisted self-interviews (ACASI) while they attended their regular clinic appointment at a
Ryan White clinic located in Macon, GA. Measures included demographics, health
information, experiences of enacted stigma in the past year, stress and coping with the
most impactful enacted stigma event. Medical information (viral load, CD4 count, clinic
attendance, and medications) was abstracted from patient charts for a period of 6
months prior to their survey date.
Results – A total of 96 individuals endorsed experiencing enacted stigma in the past
year, and the sample endorsed moderate levels of internalized HIV stigma. Individuals
who endorsed enacted stigma tended to have more negative psychosocial and mental
health outcomes. Internalized stigma related to stress indexed on the most salient event
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of enacted stigma in the past year as well as maladaptive coping strategies used to
cope with discriminatory experiences. There was not evidence in multivariate analyses
that stress or maladaptive coping mediated effects of internalized stigma on medication
adherence. There was also not a moderating effect of adaptive coping strategies on
medication adherence in this sample.
Conclusion – HIV stigma appears to have short-term effects on mental health, which
could lead to long-term effects on physical health. Longitudinal investigations are
indicated to uncover the mediating and attenuating mechanisms of HIV stigma on health.
Stigma should be addressed in the context of health promotion interventions for PLWH
given its implications on mental health and wellbeing.
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HIV-related Stigma and Health among People Living with HIV in Middle Georgia:
Examining the Roles of Stress and Coping

Addressing health disparities faced by individuals living with human
immunodeficiency virus (HIV), including HIV-related stigma is a public health priority.
HIV stigma – defined as the social devaluation and discrediting of people living with HIV
(PLWH) – is a significant barrier to improving the health and wellbeing of PLWH (Link &
Phelan, 2001; Mahajan, et al., 2008; Hatzenbuehler, Phelan, and Link, 2013). Stigma
produces limitations across all levels of prevention and management of HIV.
Consequences of HIV stigma include reduced uptake of HIV-related information and
testing, lower linkage and retention in HIV care, lower treatment adherence, accelerated
HIV disease progression, poorer mental health, lower likelihood of HIV status disclosure,
and rejection and isolation from family, friends, and community supports (Fife & Wright,
2000; Herek, Capitanio, & Widaman, 2003; Vanable, Carey, Blair, & Littlewood, 2006;
Logie & Gadalla, 2009; Katz, et al., 2013; Earnshaw, Smith, Chaudoir, Amico, &
Copenhaver, 2013). Stigma functions as a chronic stressor in the lives of those who are
stigmatized, serving as a mechanism that undermines health and drives health
inequalities (Phelan, Link, & Tehranifar, 2010). Recently, the National AIDS Strategy
(2015) called for the reduction of HIV stigma as a means to improve health among
PLWH:
“The United States will become a place where new HIV infections are rare, and
when they do occur, every person, regardless of age, gender, race/ethnicity,
sexual orientation, gender identity or socio-economic circumstance, will have
unfettered access to high quality, life-extending care, free from stigma and
discrimination.” (White House Office of National AIDS Policy, 2015, p.3)
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However, stigma has proven difficult to reduce and eliminate at the societal and
structural level. Theoretical and meta analytic work suggests the importance of
understanding the dynamic effects of HIV stigma on individuals, and finding avenues to
protect people from the harmful impact of stigma (e.g., Earnshaw, Lang, Lippitt, Jin, &
Chaudoir, 2015; Earnshaw, Bogart, Dovidio, & Williams, 2013; Logie & Gadalla, 2009).

Defining Stigma and Its Mechanisms
Early research on HIV stigma was built on Erving Goffman’s (1963)
conceptualization of stigma that characterized people with an “attribute that is deeply
discrediting” (p.3). Note that Goffman’s writing was published well before the onset of
the HIV epidemic in the 1980’s, and he focused his conceptualization on those with a
visible “identity,” which allowed observers to link the attribute to stereotypes (Jones, et
al., 1984). Stigma is a complex phenomenon and there remains some variation in how it
is defined and conceptualized. To the preceding definition, Link and Phelan (2001)
added important components of stigma: that it leads to a degree of separation between
“us” (the stigmatizers) and “them” (the stigmatized), and that identification of a
stigmatized trait leads to status loss and adverse outcomes. Discrimination, prejudice,
and stereotyping encompass behavioral, affective, and cognitive responses that occur
as a result of a more global stigma process (Deacon, 2006). Applied to the HIV
epidemic, this process likely occurs as a means for people to distance themselves from
risk of infection by blaming and marginalizing other groups for contracting and
spreading the disease (e.g., people who engage in risky sexual behaviors, sex workers,
gay and bisexual men, transgender individuals, IV drug users, people living in poverty,
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racial minorities, women). Moreover, this process of stigmatization and discrimination
occur in the context of a structure of social and economic power (Link & Phelan, 2001;
Mahajan, et al., 2008). From a sociological perspective, “stigma and stigmatization
function – quite literally – at the intersection of culture, power, and difference” (Parker &
Aggleton, 2003, p.17). As such, HIV stigma often occurs in tandem with other socially
devalued characteristics (e.g., socioeconomic status, race, gender, sexual orientation;
Parker & Aggleton, 2003). These aforementioned perspectives offer context to the
problem of HIV stigma as a social process, but additional work is needed to understand
how stigma impacts individuals.
Earnshaw and Chaudoir (2009) synthesized the literature on stigma’s impact on
individuals by reviewing HIV stigma measures. They found three distinct mechanisms of
HIV-related stigma conceptualized in their model, the HIV Stigma Framework. Enacted
stigma (also referred to as perceived stigma) is the prejudice and discrimination from
others that are experienced by PLWH. Anticipated stigma describes expectations that
PLWH have that they will be discriminated against because of their HIV status.
Internalized stigma (also referred to as self stigma) refers to the extent to which PLWH
apply negative beliefs and feelings about HIV/AIDS to themselves. Since their review,
Earnshaw and colleagues (2013) hypothesized and tested potential relationships
between the HIV stigma mechanisms and health outcomes. For instance, enacted
stigma demonstrates greater association with physical health outcomes (e.g., CD4 cell
count). Anticipated stigma is associated with adverse behavioral outcomes such as
lower engagement in medical care. Internalized stigma is associated with negative
emotional states (e.g., helplessness). In their review, Earnshaw and Chaudoir (2009)
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pointed to the importance of building an understanding of who is affected by HIV stigma,
how they are affected, and what the outcomes of HIV stigma mechanisms are at the
individual level as a way to study this complex construct moving forward.

Stigma and Health
As the concept of stigma has evolved, researchers are increasingly interested in
explaining and quantifying its impact on health. A major body of work in this field has
introduced and investigated the minority stress model. This model implies causal
relationships between sexual minority group status, increased stress, limited coping
resources, and adverse health outcomes, including HIV risk (Meyer, 1995). A separate
literature has investigated the implications racism and race-related discrimination on
health (e.g., Brondolo, Brady, Pencille, Beatty, & Contrada, 2009). Moreover, stigma
has become a focus in the area of HIV behavioral research (Earnshaw, et al., 2013;
Rueda, et al., 2016). Despite these relatively separate tracks of research, they share
commonalities in that the models define stigma and discrimination as stressors in the
lives of those who experience them. They also promote coping resources as buffers to
the effects of stigma that drive health disparities. Regardless of stigmatized
characteristic, Hatzenbuehler, Phelan, and Link (2013) recommend the synthesis of
models of health disparities for members of stigmatized groups to better understand
stigma as a social determinant of health.
Some more comprehensive models have grown out of the literature that may
explain some of the dynamic processes of stigma and its impact on health. Pascoe and
Richman (2009) proposed a conceptual model, which they supported with a meta-
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analysis to describe how perceived discrimination affects physical and mental health
outcomes. Perceived discrimination in their model maps well onto the construct of
enacted stigma. In Pascoe and Richman’s model, discrimination is conceptualized as a
social stressor that affects health through the mechanism of physical or psychological
stress responses, as well as engagement in negative health behaviors (or conversely,
the lack of engagement in positive health behaviors).
Stigma and stress. Among PLWH, stress can impact HIV disease progression
and it has been associated with lower CD4 cell counts (Leserman, 2003). Stress is an
important variable to monitor in PLWH as it can impede immune functioning and
interfere with achievement of viral suppression.
From a mechanistic perspective, there are a few different ways stigma functions
as a stressor. Enacted stigma is often explicit interpersonal exclusion that is
unpredictable and uncontrollable. Given the ambiguousness that sometimes underlies
discriminatory experiences, people may have difficulty identifying the stressor and
deciding on an appropriate coping response (Williams, Neighbors, & Jackson, 2003).
Exposure to discrimination has been linked to physiological responses characteristic of
a stress response including increased heart rate, increased blood pressure, and
elevated cortisol levels (e.g., Clark, Anderson, Clark, & Williams, 1999). Pascoe and
Richman recommended future investigation of chronic and recent events of
discrimination that appear to have the most deleterious effect on health. Moreover, the
mediated relationship of enacted stigma to physical health via stress may occur as
individuals increasingly experience stigmatizing events. With increasing exposure to
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stigma, physiological and psychological stress responses are activated and can lead to
a chronic negative emotional state (Pascoe & Richman, 2009).
Anticipated stigma functions somewhat differently as a stressor. Instead of being
marked by events of exclusion, anticipated stigma creates vigilance to negative
treatment by others. This leads to a chronically aroused state that can deteriorate
coping resources over time (Stuber, Meyer, & Link, 2008). Indeed, individuals living with
chronic illnesses who report high levels of anticipated stigma also report high levels of
perceived stress that impacts their quality of life (Earnshaw, Quinn, & Park, 2012).
Internalized stigma creates stress through the process of ongoing cognitive
appraisals of negative societal attitudes applied to oneself. Internalized stigma has been
associated with greater psychological distress (Ross & Rosser, 1996; Boone, Cook, &
Wilson, 2016). Furthermore, individuals with internalized stigma are likely more
sensitive to anticipated and enacted stigma (Chesney & Smith, 1999), and they likely
have fewer interpersonal resources to cope (Helms, et al., 2016).
Coping with Stigma. Researchers hypothesize that coping resources buffer
against the potentially negative effects of enacted stigma on health (Pascoe & Richman,
2009; Earnshaw, et al., 2015). In their meta-analytic review, Pascoe and Richman
(2009) hypothesized about the role of coping resources in buffering the impact of
enacted stigma on health. Similarly, Earnshaw, and colleagues (2013) indicated the
need to investigate strength-based, modifiable resources that may moderate the effect
of stigma on health outcomes. Few studies in the area of HIV have looked at specific
coping strategies PLWH use to manage their experiences of HIV stigma. Varni, et al.
(2012) examined the role of engagement and disengagement coping strategies on
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depression, anxiety, and self-esteem among PLWH. Their findings suggested that
engagement coping attenuated the relationship between stigma and self-esteem. Social
support, the tangible and emotional support offered by others, is a promising resource
for individuals facing stigma. Social support has demonstrated buffering effects on
health in the more global health literature (Cohen, 2004). Seeking social support may
help people regulate their emotions and problem solve under stress related to stigma
(Earnshaw, et al., 2013). Results on the effect of social support as a coping resource
have been mixed with some finding evidence that social support serves as a moderator
and some finding no effect of social support (e.g., Earnshaw, et al., 2015; Logie, et al.,
2012). Additional research is needed to determine the existence and magnitude of
these relationships, and should also account for a variety of different coping strategies
such as seeking other supportive resources (e.g., religion), and use of cognitive coping
strategies (e.g., acceptance).
Maladaptive or avoidant coping strategies should also be addressed, particularly
given the uncontrollable nature of stigma. Previous research suggests that individuals
may engage in negative health behaviors like alcohol use as a means to escape the
negative emotional and cognitive experiences associated with stigma (Pascoe &
Richman, 2009). Given the stress and coping framework, maladaptive coping strategies
like substance use become available when adaptive coping resources become
overwhelmed by stress (Litt, Kadden, & Kabela-Cormier, 2009). Furthermore, high
levels of disengagement coping have been associated with higher levels of anxiety and
depression among PLWH reporting experiences of enacted stigma (Varni, et al., 2012),
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creating a problematic cycle between distress and avoidance. These maladaptive or
avoidant coping strategies may complicate clinical outcomes for PLWH.

Health outcomes pertinent to PLWH. Health outcomes among people living with
HIV are evaluated along the HIV treatment cascade, or care continuum (Gardner, et al.,
2011; Mugavero, et al., 2013). The continuum monitors the proportion of PLWH who are
connected to testing resources and diagnosed; the number of people diagnosed who
are linked to medical care; the number of people who remain engaged in their medical
care; as well as the number of people prescribed antiretroviral treatment (ART). For
individuals who are engaged in care and taking ART, the optimal outcome is HIV viral
suppression, which reflects antiretroviral medication adherence. Adherence to ART and
viral suppression improve the health of PLWH and significantly reduce the likelihood of
HIV transmission (Cohen, et al., 2011). However, only about 30% of individuals who are
living with HIV are virally suppressed according to estimates by the Centers for Disease
Control (Bradley et al., 2014). This indicates the importance of psychosocial and
behavioral factors that interfere with PLWH achieving optimal health. As stated in the
National HIV/AIDS Strategy (2015), Americans with the least access to prevention and
treatment services are those most affected by HIV. The writers further pointed to the
management of stigma as one means to end these disparities.
The literature that links stigma to health outcomes has steadily grown over recent
years. A meta-analysis of 24 studies indicated that HIV stigma is associated with
negative mental and physical health outcomes including increased depression and
greater evidence of HIV disease progression (Logie & Gadalla, 2009). Katz and
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colleagues (2013) reviewed and meta-synthesized 75 quantitative and qualitative
studies finding stigma as an inhibitor to ART adherence. Despite the growth of
academic inquiry in this area, relatively little is known about the mechanisms that
explain the relationship between stigma and health in the HIV literature (Rueda, et al.,
2016). Rao and colleagues (2012) found that depressive symptoms partially mediate
the relationship between HIV-related stigma and medication adherence. Another group
of researchers found mediating effects of interpersonal factors on the relationship
between stigma and medication adherence (Helms, et al., 2016). No studies to our
knowledge have explicitly examined the roles of stress related to stigma and coping with
enacted stigma in relationship to medication adherence or other health outcomes.
In the consideration of overall health and wellbeing among PLWH, co-occurring
chronic and acute conditions should be considered in the management of HIV-related
health. Mixed results have been found regarding the burden of co-morbid health
conditions and retention in medical care (Corless, et al., 2008; Crawford, 2015). Some
researchers have linked co-morbid health conditions and polypharmacy with lower ART
adherence (Krentz & Gill, 2016). Examining co-occurring medical needs may be
important for the assessment of health among PLWH, and a potential addendum to the
HIV treatment cascade.

The HIV Epidemic in the State of Georgia
The Southern region of the United States is an important area for research related to
HIV-related stigma and health. The incidence of new HIV diagnoses as of 2014 was the
highest in the South with a rate of 18.5 per 100,000 people (for comparison the national
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rate was 13.8 per 100,000 people; CDC, 2016). Not only are more people living with
HIV in the South, more people are progressing to diagnoses of AIDS and dying from
AIDS (CDC, 2015a). Considering the treatment options that are available to PLWH,
these disparities must be considered in light of social determinants.
The state of Georgia ranked fifth out of the 50 states in the U.S. in the number of
adults living with HIV in 2013 (CDC, 2015b). While over 60% of HIV cases are localized
to the Atlanta and metropolitan-Atlanta area, rates of HIV in other health districts are
significant given the population distribution in those areas. As of 2014 (the latest year
for which data are available), the rate of PLWH in the North Central (Macon) area was
406 per 100,000 persons; the rate of HIV infection in the state of Georgia was 527 per
100,000 persons (Georgia Department of Public Health, 2016).
In Georgia, there are few resources for PLWH outside of the metro Atlanta area.
Stigma is a high risk for individuals diagnosed with HIV living in suburban and rural
Georgia with sparse opportunities for support. Furthermore, little research has been
carried out on the experiences of stigma and health among PLWH who reside in middle
Georgia. This represents a novel population for which it is important to investigate how
HIV stigma may act as a barrier to health.

Current Study
The purpose of the present study is to build on the existing literature about the
experience of HIV stigma and its relationship to health among PLWH living in the
southern United States and to explore potential mechanisms of that complex
relationship. The first research question aims to answer whether there is a direct
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relationship between internalized HIV stigma and health. Consistent with models of
stigma and discrimination on health, a negative relationship between internalized HIV
stigma and HIV-related health outcomes is expected, such that participants who
endorse higher levels of stigma will have lower medication adherence, and be less likely
to be virally suppressed.
The next research questions will address potential mediating effects of
internalized HIV stigma, including stress and maladaptive coping strategies. It is
expected that both the stress associated with enacted stigma and maladaptive
strategies for coping with events of enacted stigma will strengthen the relationship
between internalized HIV stigma and negative health outcomes. The final research
question will assess the potential moderating effect of adaptive coping responses such
as acceptance, seeking social support, and spiritual coping. It is expected that adaptive
coping resources will buffer the relationship between HIV stigma and HIV-related health
outcomes. The proposed model illustrating these hypothesized relationships is depicted
in Figure 1. Overall, the current study seeks to understand mechanisms of HIV-related
stigma on health within a stress and coping framework.

Methods
Participants and Procedures
Participants were recruited from a Ryan White funded clinic located in Macon,
GA between February and May 2016. To be included in the study, participants had to
be 1) 18 years or older, 2) able to understand all study procedures and provide informed
consent, 3) HIV-positive, and 4) a clinic patient attending an initial or update
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appointment. Patients were approached by a research staff member in the clinic waiting
area and informed about the opportunity to participate in the study. To reduce any
pressure on patients to participate in the clinic survey, no clinic staff members were
involved in recruiting participants. If a patient expressed interest, they were provided an
e-tablet with headphones that administered the consent form via audio-computer
assisted self-interview (ACASI). After reading and/or listening to the consent form
participants were invited to ask any questions and then signed a consent form if they
agreed to the study procedures. A total of 258 people were approached, 58 individuals
refused to participate, and 199 patients agreed to complete study procedures (77%).
Following consent, participants were again provided with an e-tablet with
headphones and completed their ACASI survey that was de-identified with a participant
identification number. The survey took approximately 30 minutes to complete.
Participants were each compensated for their time with a $15 gift card.
As part of informed consent, participants provided release of information to
access health information from their electronic medical record including clinic
attendance, viral load, CD4 count, and medications inclusive of the date of their current
appointment to six months prior. Medical data were collected through retrospective
chart review, linked by date of birth. No other identifying information was collected.
Research staff collected and coded chart data. No clinic staff members were involved in
chart data collection to protect participant privacy. The University of Connecticut and the
Mercer University Institutional Review Boards approved all study procedures. In addition,
a Certificate of Confidentiality was sought to protect participants’ information.
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Self-Report Measures
Socio-demographic Information. Participants were asked their age, selfidentified gender, race, sexual orientation, education attainment, employment status,
religion, and history of incarceration. Indicators of poverty were assessed including
availability of transportation, housing security, and food sufficiency in the past month.
Health Information. Health information including the date of their first HIV
antibody test, whether they are currently taking antiretroviral medications, and questions
about their antiretroviral medication adherence, including a visual analog scale (VAS) of
adherence in the past month, were asked. We dichotomized self-reported medication
adherence as adherent (reported 85% on VAS) and non-adherent (<85% on VAS).
Questions were also asked to assess whether participants hid their antiretroviral
medications (e.g., physically hide medications, take medications out of their bottles, tell
people medications are for something else). Service utilization was assessed including
attendance to a mental health counselor, substance use counselor, HIV support group,
and/or Alcoholics Anonymous/Narcotics Anonymous group in the past month.
Health-related quality of life (HRQL) was also assessed using items from the
Center for Disease Control and Prevention’s Behavioral Risk Factor Surveillance
Survey health-related quality of life items (CDC, 2000). These items included
assessment of general health status, number of days in the past month that physical
health was not good, number of days in the past month when activity was limited as a
result of physical health, number of days in the past month when pain was present, and
number of days in the past month when health was good.
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Depressive symptoms were assessed using the Center for Epidemiological
Studies - Depression Scale (CES-D; Radloff, 1977). The CES-D includes 20 items
assessing cognitive, affective, and vegetative symptoms of depression. Radloff (1977)
suggested a clinical cutoff of 16 to indicate possible depression, or a stricter cutoff of 23
to indicate probable depression. Reliability of the CES-D was good in the current
sample (Cronbach’s alpha = .889). In accordance with Kalichman, Rompa and Cage’s
(2000) findings that somatic symptoms on the CES-D may be explained by HIV
symptoms, the cognitive/affective item score on the CES-D was also calculated and had
acceptable internal consistency (Cronbach’s alpha=.798).
Alcohol use and symptoms of alcohol dependence were assessed with the
Alcohol Use Disorder Identification Test (AUDIT; Saunders, et al., 1993; Schmidt, Barry
& Fleming, 1995). The AUDIT, developed by the World Health Organization (WHO),
includes 10 items used to assess alcohol use and problematic behaviors resultant of
alcohol use. A cutoff score of 8 or above is suggested to identify individuals who have
problematic patterns of alcohol use. Participants skipped out of the last 9 questions of
the measure if they reported they do not drink any alcohol on the first question, which
assesses alcohol consumption. This scale also showed good internal consistency in the
present sample, Cronbach’s alpha = .847. In addition, participants were asked about
their use of drugs in the past month including marijuana, cocaine, and any other drug
without a prescription.
Internalized HIV Stigma. The HIV Stigma Mechanisms Scale (Earnshaw, et al.,
2013), internalized stigma subscale (6 items) was used to assess internalized HIV
stigma. Participants responded to items assessing their negative feelings about living
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with HIV (e.g., I feel ashamed about having HIV) on a Likert scale. Higher scores
indicate greater internalized stigma (greater agreement with negative statements). In
accordance with scoring procedures carried out by the scale authors, responses across
the 6 items were averaged to create a composite score. Internal consistency of items in
the subscale was very good in the present sample, Cronbach’s alpha = .914.
Enacted HIV Stigma Checklist. Experiences of enacted HIV stigma (perceived
discrimination) were assessed using 20 questions adapted from multiple enacted HIV
stigma measures. Items were selected from the enacted stigma subscale of the HIV
Stigma Mechanisms Scale (Earnshaw, et al., 2013), the HIV Stigma Scale (Bunn, et al.,
2007; Berger, et al., 2001), and the Multiple Discrimination Scale – HIV version (Bogart,
Landrine, Galvan, Wagner, & Klein, 2013). Participants were asked about the frequency
with which they experienced any of the items in the past year due to their HIV-positive
status on a scale: 5 = almost everyday, 4 = at least once a week, 3 = a few times a
month, 2 = a few times this year, 1 = about once this year, 0 = never. Responses across
the 20 items were averaged to create a composite score. Reliability of items was very
good in this sample, Cronbach’s alpha = .934.
Stigma-Related Stress. For every item on the enacted HIV stigma checklist that
participants endorsed occurring in the past year, they rated the negative impact (stress)
that the event had on them. This involved asking one item for every enacted stigma
event that a participant endorsed: “Please rate the level of negative impact this event
had on you on a scale from 0 (no negative impact at all) to 10 (the most severely
negative event you can imagine).” This stress item is adapted from the UCLA Life Event
Stress Interview (Hammen, Adrian, Gordon, Burge, Jaenicke, & Hiroto 1987), which is
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an interview schedule designed to assess chronic and acute life events/stressors. A
composite stress score was calculated for each participant by averaging their stress
scores across the 20 enacted stigma items. Participants’ stress rating on the most
impactful enacted stigma event in the past year was used in multivariate analyses.
Coping. The Brief COPE (Carver, 1997) was used to assess coping strategies
used to deal with the most stressful experience of enacted HIV stigma in the past year.
The Brief COPE is a 28-item, 14-scale measure of coping styles that was adapted from
the original 60-item COPE (Carver, Scheier, & Weintraub, 1989), a validated measure
of dispositional and situational coping. The 14 scales in the Brief COPE include Selfdistraction (“I've been turning to work or other activities to take my mind off things.”),
Active coping (“I've been concentrating my efforts on doing something about the
situation I'm in.”), Denial (“I've been refusing to believe that it has happened.”),
Substance use (“I've been using alcohol or other drugs to make myself feel better.”),
Use of Emotional Support (“I've been getting comfort and understanding from
someone.”), Use of instrumental support (“I’ve been getting help and advice from other
people.”), Behavioral disengagement (“I've been giving up trying to deal with it.”),
Venting (“I've been saying things to let my unpleasant feelings escape.”), Positive
reframing (“I've been looking for something good in what is happening.”), Planning (“I've
been thinking hard about what steps to take”), Humor (“I've been making jokes about
it.”), Acceptance (“I've been accepting the reality of the fact that it has happened.”),
Religion (“I've been praying or meditating.”), and Self-blame (“I’ve been criticizing
myself.”). Carver (1997) made no recommendations for categorizing coping styles (e.g.,
maladaptive vs. adaptive coping; problem-focused vs. emotion-focused) beyond the
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individual scales on the Brief COPE, but did recommend creating higher order factors
from one’s data (Carver, et al., 1989) if appropriate to the research question at hand.
Before beginning the Brief COPE, participants were first asked to choose which
enacted stigma event out of those they endorsed in the past year had the most negative
impact on them. They were then asked to think about the last time that event happened
and what they did to cope with it, by rating items on the Brief COPE on a scale from 1 (I
haven’t been doing this at all) to 4 (I’ve been doing this a lot). The Brief COPE was
designed to concisely assess coping strategies related to a specific stressor, and it has
been widely used in health populations, including PLWH (e.g., Turner-Cobb, et al.,
2002). Internal consistency of the Brief COPE was very good in the present sample,
Cronbach’s alpha = .923

Chart Abstracted Health Data
Research staff abstracted medical information from patient charts, linked to study
identification number by date of birth. Information abstracted ranged from the date of
study survey over the six months prior. Viral load and CD4 cell counts were abstracted
from participants’ medical charts to verify medication adherence and assess HIV
disease progression. Viral suppression (undetectable viral load) was defined as viral
load of less than 20 copies/ml, which is a sensitive threshold and how the clinic defined
an undetectable viral load. A CD4 threshold of 200 cells per cubic mm of blood was the
cutoff for disease progress, indicating a damaged immune system. In addition, clinic
appointment attendance was abstracted for the six months prior to the date of survey
completion. Non-attendance was defined as missing one appointment without
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cancellation, or rescheduling more than one appointment in the past six months, similar
to previous of measures of clinic non-attendance (e.g., Catz, McClure, Jones, &
Brantley, 1999). Participants’ current (active) medications were also assessed to
confirm antiretroviral regimen and to determine the presence of co-morbid health
conditions. Total number of active medications was used as a proxy measure of the
burden of co-occurring medical conditions.

Data Analytic Strategy
Prior to analysis, all data was cleaned and checked for technical or
computational errors. All analyses were done in SPSS version 21. Descriptive analyses
were carried out to assess the distribution of study variables and to describe the sample.
Correlation analyses were also conducted to examine relationships between
demographic and health variables in the sample. Frequency and descriptive analyses
were used to describe endorsement of experiences on the enacted stigma checklist that
was developed for this study.
Consistent with the literature on enacted stigma and discrimination (e.g., Bogart,
et al., 2013), not all participants endorsed an experience of enacted stigma in the past
year. Chi-square comparisons for categorical variables and F tests for continuous
variables were used to assess group differences between participants who endorsed an
enacted stigma event in the past year (n=96) compared to those who denied
experiencing any events in the past year (n=103).
The remainder of analyses was carried out on the sample of participants who
endorsed experiencing enacted stigma in the past year. Bivariate analyses were used to
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determine relationships between demographic variables and outcome variables (i.e.,
stress, coping, health indicators) to identify control variables to be used in analyses.
Correlations were also examined between stigma, stress, coping, and health variables.
Finally, multivariate analyses were used to examine the relationships between
each predictor variable in the path model and health outcome variables. We started by
conducting a series of linear and logistic regression analyses to evaluate the
relationship between predictors and health outcomes. Next, the hypothesized study
model was tested using path analysis via Preacher and Hayes regression-based
PROCESS tool (Model 14 with 2 mediators and 1 moderator; Hayes, 2013).
Dichotomous medication adherence was the outcome variable in the path analysis
given the precedent in the literature described in the introduction. Bootstrapping was
used to test for effects without assuming normality in the sampling distribution
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002).

Results
Description of socio-demographic characteristics
Participants included a total of 199 men and women. A description of the study
sample’s demographic information can be found in Table 1. Participants ranged in age
from 18 to 77 years old, with a mean age of 45.7 (SD: 12.0). A majority of the sample
identified as male (62%). Nine individuals (5%) identified as transgender. A large
majority identified their race as African American/Black (84%); 13% identified as White,
1% Hispanic or Latino, 2% as biracial or multiracial, and 1% identified as ‘Other.’ A
relative majority identified their sexuality as heterosexual (56%), 30% identified as
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homosexual, and 11% identified as bisexual. Most participants identified their religion as
Christian (75%). Most of the sample reported completing high school or beyond (77%),
and 23% reported not completing high school. In terms of employment, 13% were
working full-time, 10% part-time, 40% were on disability, 35% were unemployed, and
3% were students. A total of 100 participants (50%) endorsed a history of incarceration.
Participants represented 34 unique zip codes, traveling between approximately 0
and 73 miles to the clinic (M=19.6 ± 14.0). A total of 34 participants (17%) reported
having unreliable transportation (i.e., could not get to the clinic or to a place to get meals
because they did not have a ride) in the past month. A total of 23 participants (12%)
reported having unstable housing (i.e., did not have a place to stay or worried about
having a place to stay) in the past month. Also, in the past month, 59 participants (30%)
endorsed having insufficient food (i.e., chose between spending money on medicine or
food, ran out of food, ran out of money for food or could afford enough food, or ate less
than needed because there was not enough food).

Health and Medical Characteristics
Self-reported health information. Health-related characteristics of the sample
are reported in Table 2. Participants had been living with HIV for an average of 13.5
years (SD: 8.7, range: 0-36 years). Only 13 participants (7%) reported that they
attended an HIV support group in the past month. The vast minority of the sample, 4%
(n=9) reported not currently taking antiretroviral medications. On a visual analog scale,
participants reported taking 85.7% (SD: 26.3, range: 0-100%) of their medications in the
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past month on average. Nearly half (42%) of the sample reported that they had made
attempts to hide their antiretroviral medications in the past month.
In terms of psychological health, the mean score on the CES-D was 15.6 (SD:
11.5, range: 0-52), slightly below the recommended clinical cutoff for possible
depressive symptoms suggested by Radloff and colleagues (1977). A total of 79
participants (40%) met or exceeded the clinical cutoff of 16 indicating possible clinical
depressive symptoms. By increasing the clinical cutoff to 23, indicating probable
depression, 48 participants (24%) met or exceeded the cutoff. On the cognitive/affective
items, the mean score was 8.3 (SD: 6.4). Only 23 participants (12%) reported they had
seen a mental health counselor in the past month.
On the AUDIT total scores were considerably variable with a mean of 3.6 (SD:
5.4, range: 0-33), and 75 participants reported never drinking alcohol in the past year. A
total of 34 participants (18%) met or exceeded the clinical cutoff of eight, suggesting
problematic alcohol use. Only 12 participants (6%) reported they had seen a substance
use counselor in the past month, and 27 participants (14%) endorsed attending
Alcoholics Anonymous/Narcotics Anonymous groups in the past month.
Chart abstracted health data. According to clinic appointment attendance data,
approximately half (54%) of the participants attended all of their scheduled
appointments in the past six months, while 46% missed an appointment or cancelled
more than one appointment. The modal number of appointments scheduled in the past
six months was 3 (range: 2-5). The average number of active medications listed in
participants’ charts was 5.6 (SD: 3.8), including an average of 1.9 (SD: 1.2) HIV
medications and 3.7 (SD: 3.4) medications for other conditions. Viral load data showed
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that 64% of the sample had an undetectable viral load. Only 10% of the sample had a
CD4 cell count below 200 cells per cubic millimeter of blood, indicating a significantly
impaired immune system.
Co-occurring health conditions were estimated by active medications listed in
participants’ medical records. Nearly half of the sample received treatment for
cardiovascular/cerebrovascular conditions (n=97, 49%). A total of 74 individuals (37%)
were receiving treatment for co-occurring infections (bacterial, viral, or fungal).
Psychotropic medications were the next most common active medications among
approximately one third of the participants (n=66; 33%); with 58 participants (29%)
prescribed antidepressant treatment. The next most common active medication was
pain treatment among 25% (n=50) of the sample.
Description of stigma experience
The mean score on the internalized stigma subscale was 2.4 (SD: 1.2, range 1-5).
This score indicated that participants tended to disagree or feel uncertain that they had
internalized HIV stigma. A total of 96 (48%) participants endorsed experiencing at least
one event of enacted stigma in the past year. A full description of the enacted stigma
measure can be found in Table 3. On average, participants reported experiencing
between two and three different types of enacted stigma events (range: 0-20). They
endorsed being treated differently by people most (31%), followed by being rejected by
a potential sexual or romantic partner (23%). Events with the least frequency of
endorsement were having one’s personal property stolen or damaged (2%), and being
physically assaulted or beaten (3%).
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Descriptive data regarding the enacted stigma events participants selected as
the most impactful in the past year are show in Table 4. Participants tended to
experience a moderate level of stress (M: 4.8, SD: 3.3) in reaction to the most impactful
enacted stigma event. Averaging stress across all items showed relatively low, but
variable ratings of the negative impact of enacted stigma events in the past year (M: 1.5,
SD: 2.0, Range: 0-8.8). The frequency of events rated as most impactful ranged from
about once in the past year (38%), a few times in the past year (23%), a few times per
month (8%), at least once a week (4%), to almost everyday (19%).
When comparing between groups of participants who endorsed experiencing
enacted stigma in the past year versus those who did not endorse experiencing an
event (Table 5), they did not differ significantly on any demographic variables. People
who endorsed enacted stigma in the past year were more likely to have food
insufficiency (2(2, N=199)=15.2, p<.001). Comparisons among health and medical
variables are shown in Table 6. Groups differed in that those who endorsed an event of
enacted stigma in the past year had higher levels of depression (F(1, 190)=10.1,
p=.002); they scored higher on the AUDIT (F(1, 195)=7.1, p=.008), and they had higher
internalized HIV stigma (F(1, 195)=13.7, p<.001).

Brief COPE factor analysis
As recommended by Carver (1997), the present data were used to identify
categories of coping using the Brief COPE in the population of interest. A Principal
Component Analysis was conducted with a Varimax rotation. The 14 scales of the Brief
COPE were entered as variables rather than using individual items. Correlations
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between the 14 subscales are presented in Table 7. The cutoff for factor loadings was
set to .50 as recommended by Comrey and Lee (1992). The factor analysis yielded 3
factors with Eigenvalues greater than 1 that accounted for 61% of the total variance.
The 3-factor structure with factor loadings is shown in Table 8. Based on the factor
structure, the 3 factors are described as follows: maladaptive coping (Denial, Substance
use, Behavioral disengagement, Venting, Humor, Self-blame; accounting for 22% of
total variance), adaptive cognitive coping (Self-distraction, Active coping, Positive
reframing, Planning, Acceptance; 22% of total variance), and adaptive supportive
coping (Emotional support, Instrumental support, Religion; accounting for 17% of total
variance). These factors align with other published factor analyses of the Brief COPE
with populations affected by HIV (Prado, et al., 2004). Composite scores were
calculated for each of the coping factors. Given that the proposed model for this study
included adaptive coping as one variable, the adaptive cognitive coping and supportive
coping were combined into one variable composite score for analysis. A description of
Brief COPE subscales and factors in reaction to the most impactful event of enacted
HIV stigma in the past year is shown in Table 9. The approaches to coping that were
endorsed most frequently in this sample included acceptance, religious coping, and
positive reframing.

Bivariate Analyses
Exploratory correlation analyses in the full sample. Correlations were first
examined among sociodemographic and mental and physical health variables in the full
sample to confirm validity of measures (e.g., medication adherence self-report measure
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was associated with viral load abstracted from medical record). Correlations are shown
in Table 10. Measures of internalized and enacted stigma were positively correlated (r=0.36, p<.001). Internalized stigma was related to both depressive symptoms (r=-0.43,
p<.001) and alcohol use (r=-0.21, p=.003); while enacted stigma related only to
depressive symptoms (r=-0.36, p<.001). Internalized stigma was negatively correlated
with total number of active medications (r=-0.14, p<.05). Viral load detectability was
negatively related VAS medication adherence (r=-0.32, p<.001) and viral load status
related to immune functioning (=0.25, p=.001) as expected.
Relationships between sociodemographic characteristics and outcomes.
Correlations between demographic and study variables were examined first to
determine which demographic variables to control for in multivariate analyses (Table 11).
Employment (working vs. not working) was associated with stress related to the most
impactful enacted stigma event in the past year (r=-0.21, p=.05). Employment was also
associated with maladaptive coping (r=-0.28, p<.01). Age (r=0.44, p<.01), years since
HIV diagnosis (r=0.38, p<.01), gender (r=0.25, p=.01), and employment (r=-0.32, p<.01)
were all associated with total number of active medications. Gender (=-0.22, p=.03),
sexual minority status (=0.26, p=.01), and unstable housing (=0.26, p=.01) all related
to viral load (detectable vs. undetectable). Education attainment was associated with
having a CD4 cell count below the threshold of 200 (r=-0.23; p=.03). Significant
covariates were controlled for in analyses of respective outcome variables (e.g.,
education was controlled for when CD4 cell count was the outcome variable).
Relationships among study variables. As expected, internalized stigma was
significantly correlated with stress indexed on enacted stigma (r=0.37, p<.01),
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maladaptive coping (r=0.47, p<.01), and adaptive coping (r=0.24, p=.02). Stress
associated with the most impactful event of enacted stigma was positively associated
with both maladaptive (r=.31, p<.01) and adaptive coping (r=0.25, p=.02). Among the
health variables, medication adherence was significantly related to viral load (=-0.30,
p<.01), viral load status was correlated with CD4 cell count (=0.24, p=.02), and total
number of active medications was also related to CD4 cell count (r=0.27, p<.01).
Multivariate relationships of HIV stigma on health
Individual regression analyses were conducted to examine the relationships
between study variables and HIV-related health outcomes. Results from linear and
logistic regression analyses are presented in Table 12. First the relationships between
the independent variable (internalized stigma), proposed mediator variables (stress and
maladaptive coping), and moderator variable (adaptive coping) were examined.
Internalized HIV stigma significantly predicted stress associated with the most impactful
event of enacted stigma B(SE)=0.92(0.26), p=.001; maladaptive coping
B(SE)=0.55(0.11), p<.001; and adaptive coping B(SE)=0.29(0.12), p=.02. The only
health outcome predicted by internalized HIV stigma was CD4<200 AOR=2.15(0.11),
95% CI [1.04-4.46], p=.04.
Path analysis with bootstrapping was used to test the proposed study model.
Results of the path analyses are presented in Table 13 and are reported in
unstandardized form to promote interpretation based on the metrics used in the study.
Variables at the front of the hypothesized model were significantly related, as can be
seen in Figure 2. Specifically, internalized HIV stigma predicted stress associated with
an impactful enacted stigma event in the past year (path a =.917, p<.001, 95% CI [0.39-
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1.44]). Internalized HIV stigma also predicted maladaptive coping strategies used to
cope with enacted stigma in the past year (path b =.571, p<.001, 95% CI [0.34-0.0.80]).
However, there was no evidence that internalized HIV stigma, stress, or maladaptive
coping predicted medication adherence. Thus mediation of the relationship between
internalized stigma and medication adherence was not present. Additionally, there was
no evidence for moderation by adaptive coping strategies.

Discussion
The present study examined the relationships between HIV-related stigma and
health outcomes in a sample of PLWH attending clinic appointments in middle Georgia.
Specifically, we examined the effect of HIV stigma though the mechanisms of stress
related to a recent, salient enacted stigma experience and efforts to cope with that
event. A recent meta-analysis pointed out the lack of literature investigating the
mechanisms and attenuating factors involved in the relationship between stigma and
health outcomes (Rueda, et al., 2016). The present investigation sought to add to the
growing body of research filling that gap.
Endorsement of HIV stigma was relatively low in this sample and aligned with
previous investigations of HIV stigma in populations living in other geographic areas in
the United States (Bogart, et al., 2013; Earnshaw, et al., 2013; Chaudoir, et al., 2012;
Vanable, Carey, Blair, & LIttlewood, 2006). Overall, internalized stigma was reported in
the moderate to low range and approximately half the sample did not endorse an
experience of enacted stigma in the past year. One might expect that every person
living with HIV experiences HIV stigma. However, there are many reasons this may not
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be the case. Many individuals living with HIV do not disclose their HIV status to others,
which limits the opportunities for enacted stigma to occur. Unfortunately, this same
process may contribute to individuals not seeking the medical support they need or
attend clinic appointments at all. Disclosure was not assessed in this study so no
conclusions can be drawn about the relationship between openness about HIV status
and enacted stigma. Moreover, PLWH typically have other stigmatized characteristics
(e.g., race, gender, sexual preference), which take precedence over their HIV status or
interact with HIV-related stigma (Bogart, et al., 2013). Individuals who endorsed enacted
stigma in the past year reported moderate levels of subjective stress associated with
salient stigmatizing events, and they endorsed using several different approaches to
coping with enacted stigma. Acceptance, religious coping, and positive reframing were
the most frequently endorsed coping strategies for enacted stigma events in this sample.
Individuals who endorsed enacted stigma in the past year were more likely to have
greater food insecurity, symptoms of depression, alcohol abuse, and internalized HIV
stigma compared to individuals who did not endorse enacted stigma in the past year.
While these comparative findings may corroborate the literature linking HIV stigma to
poorer mental health outcomes among PLWH, study hypotheses were tested to
examine the relationships between HIV stigma and physical health outcomes in this
sample.
The first hypothesis predicted a negative relationship between internalized HIV
stigma and HIV-related health outcomes. Among the health outcomes in this study,
higher levels internalized HIV stigma was associated with greater HIV disease
progression based on a CD4 threshold indicating a compromised immune system (CD4

28

< 200). This finding suggests that internalization of stigma is heightened when overt
symptoms of disease present and people can no longer control disclosure of their HIV
status. In this sample, internalized HIV stigma did not significantly predict medication
adherence, viral suppression, clinic attendance, or number of active medications.
The second study hypothesis predicted co-mediating effects of stress indexed on
a salient enacted stigma event and maladaptive coping strategies on the relationship
between internalized stigma and HIV-related health outcomes, specifically medication
adherence. Internalized stigma was significantly related to stress indexed on enacted
stigma, such that every one-unit difference in internalized stigma conferred a .917
difference in stress. Internalized stigma also predicted maladaptive coping such that
one unit difference in stigma conferred a .571 difference in maladaptive coping.
However, neither of these paths mediated the relationship between internalized stigma
and health behavior, medication adherence in this case.
The final study hypothesis predicted a moderating effect of adaptive and
supportive coping strategies on the relationship between internalized HIV stigma and
health. Once again, there was not evidence in this sample supporting the moderating
role of adaptive and supportive coping resources on HIV-related health outcomes.
There are several potential reasons for the lack of statistically significant effects
found for internalized HIV stigma, stress, and coping resources on medication
adherence. First, stress and coping were indexed on a single, salient event of enacted
stigma in the past year. This may have limited the range of stressful experiences as well
as the compounding effects of multiple stigmatizing events in the past year and beyond
that time frame. It is possible that internalized and enacted stigma have short-term
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effects on mental health outcomes such as depressive symptoms and alcohol use.
Effects on physical health may compound over time and take longer to show significant
effects, especially when considering stigma as a chronic stressor in the lives of people
who are stigmatized. On the other hand, directionality of these relationships cannot be
determined from this study. Individuals with poorer mental health may be more sensitive
to HIV stigma. A next step for research in this area should make use of prospective and
longitudinal data to parse out the directions of these relationships.
Other contextual factors likely contribute to the impact of HIV stigma on health.
One could contextualize stigma in an ecological framework of health (WhettenGoldstien & Pence, 2013), which widens the potential mechanisms at the individual,
environmental, and systemic levels. Indeed, in a recently published study, authors
hypothesized that interpersonal factors contribute to the impact of HIV stigma on
medication adherence given the interpersonal nature of stigma (Helms, et al., 2016).
They found that attachment-related anxiety and concern with being seen while taking
ART medications influenced the relationship between stigma and adherence. The
present study exclusively examined intrapersonal factors of stress and coping as they
impact the relationship between HIV stigma and health and may have limited effects.
A few study limitations are worth noting. The cross-sectional approach to the
present data analysis is a chief limiting factor. Cross sectional data limits the
interpretation of mediated and moderated relationships and directionality of
relationships cannot be determined. Future research could follow participants
longitudinally to assess the effect of HIV-related stigma and its mechanisms on health
among PLWH over time. Second, levels of stigma were relatively low in this sample.
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While the relatively low endorsement of stigma may be consistent with previous findings
in the literature (e.g., Bogart, et al., 2013; Earnshaw, et al., 2013; Chaudoir, et al., 2012;
Vanable, Carey, Blair, & LIttlewood, 2006), it did limit power in conducting analyses in
this study. Given that low endorsement of internalized and enacted stigma may be
expected, larger samples should be recruited in future investigations in order to
increase power in statistical tests.
Enacted stigma in the past year was assessed exclusively based on HIV-positive
status. Intersectionality and layering of different types of stigmatized identities (e.g.,
race-based, sexual orientation, mental health and substance use, socioeconomic
status) are very likely to impact health in this population. Stigma based on HIV status
was accounted for in this study to fully understand the mechanisms of HIV-related
stigma in a population of PLWH living in the rural south. However, this may be too
narrow a focus and the wider interpersonal and intrapersonal context should also be
considered. Future research could expand on these findings to account for other types
of discrimination, or ask participants which form of discrimination is most salient in their
lives. Mixed methods approaches may also be a valuable avenue for understanding the
nuances by which HIV-related stigma influences PLWH psychologically.
Finally, the present study sample was one that was engaged in care at a
specialty HIV clinic. Consequently, conclusions cannot be drawn about the role of HIVrelated stigma and discrimination among people who have not engaged in care or who
have lapsed in their HIV care for more than six months. One could assume that
individuals not engaged or lapsed in care are likely most afflicted by HIV-related stigma.
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Some thought should be given to how to engage these individuals in future research as
well as medical care.
In spite of these limitations, this is one of few studies to exclusively assess the
role of HIV-related stigma on health outcomes, through the mechanisms of stress and
specific coping strategies indexed on recent events of enacted HIV stigma. This
approach created a fuller understanding of specific enacted stigma experienced by
PLWH living in a low resource area in the Southeast. Another strength is the use of
chart information rather than relying exclusively on self-report for health outcomes of
interest.

Conclusions
The present study examined the experience of HIV stigma in a sample of PLWH
residing in middle GA and receiving medical care at a Ryan White clinic. It also sought
to examine the mechanisms by which HIV stigma relates to health outcomes in this
population. While strong relationships were found between internalized stigma, enacted
stigma, stress, and coping; together these mechanisms did not translate to significant
health outcomes in this sample. It is possible that focusing on specific experiences of
enacted HIV stigma limited effects by not accounting for the compounding, chronic
stress of stigma. It is also possible that focusing exclusively on HIV stigma did not
account for the wider context of other stigmatized identities or the intersectionality of
stigma on health outcomes. Future research should focus on prospective and
longitudinal studies to explore the mechanisms of the effects of stigma on health in
PLWH. Qualitative investigations may also be useful to understand the nuanced effects
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of stigma in the lives of PLWH for which quantitative studies are not sensitive enough to
uncover. From a clinical perspective, individuals who endorsed experiences of enacted
HIV stigma in the past year tended to have greater psychosocial and mental health
concerns. Symptoms of depression and alcohol use likely translate to poorer physical
health over time. From a clinical intervention perspective, HIV stigma is an important
piece of the context of health disparities for PLWH and should be attended to in
interventions. Based on the moderate level of endorsement of HIV stigma in this sample
and others, individuals may not be motivated to participate in an intervention focused
specifically on stigma. But, clinicians and researchers can potentially improve mental
health outcomes by including material specific to HIV stigma so that PLWH can feel in
control of their reactions to such experiences and fully utilize their coping resources.
Comprehensive assessments of stigma in this population may be useful to determine
areas that can be targeted in intervention. Moreover, health interventions implemented
in HIV care settings, such as stress management or medication adherence or
adjustment to HIV, could include material specific to managing HIV stigma. Clinical
intervention researchers may add to these efforts by assessing the acceptability of
stigma-related content in addition to the comparative effectiveness of interventions
containing stigma-related content compared to traditionally-implemented therapeutic
interventions.
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Table 1. Descriptive statistics of socio-demographic characteristics, full sample (N=199).
Characteristic
n (%)
Age (M ± SD, range)
45.7 ± 12.0, 18-77
Gender
Male
123 (62%)
Female
74 (37%)
Transgender
9 (5%)
Race
African American/Black
167 (84%)
White
25 (13%)
Hispanic Latino
2 (1%)
Biracial or Multiracial
3 (2%)
Other
2 (1%)
Sexual Orientation
Homosexual/Same sex loving
59 (30%)
Bisexual
22 (11%)
Heterosexual/Straight
112 (56%)
Education Level
Less than HS degree
45 (23%)
HS degree or equivalent
70 (35%)
More than HS degree
84 (42%)
Employment
Working full time
26 (13%)
Working part time
19 (10%)
On disability
79 (40%)
Unemployed
69 (35%)
Student
5 (3%)
Religion
Christian
148 (75%)
Agnostic/Atheist
2 (1%)
Spiritual but not religious
20 (10%)
Other
28 (14%)
Ever incarcerated
100 (50%)
In the past month:
Unreliable Transportation
34 (17%)
Unstable Housing
23 (12%)
Insufficient Food
59 (30%)
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Table 2. Health and medical characteristics of full sample (N=199).
Characteristic
M ± SD, range, or n(%)
Years since HIV Diagnosis
13.5 ± 8.7, 0-36
Taking ARVs (self-report)
190 (96%)
Visual analog medication adherence
85.7 ± 26.3, 0-100
Medication adherence > 85%
144 (72%)
# Active medications
5.6 ± 3.8
# Antiretroviral medications
1.9 ± 1.2
# non-HIV medications
3.7 ± 3.4
Clinic attendance past 6 months:
Missed appointments
91 (46%)
Attended all appointments
108 (54%)
Most recent viral load
2432.5 ± 11517.4
Viral Load Status:
Detectable (≥20 copies/mL)
66 (33%)
Undetectable
127 (64%)
Most recent CD4 count
575.4 ± 307.3
CD4 cell count < 200
19 (10%)
CESD
15.6 ± 11.5, 0-52
AUDIT
3.6 ± 5.4, 0-33
In the past month:
Mental health counselor
23 (12%)
Substance use counselor
12 (6%)
AA/NA meeting
27 (14%)
HIV support group
13 (7%)
Health-related quality of life past month:
163 (82%)
General health  “good”
63 (32%)
Health not good  2 weeks
50 (25%)
Health kept from activities  2 weeks
56 (28%)
Pain  2 weeks
Comorbid treatment:
Pulmonary treatment
36 (18%)
Diabetes treatment
18 (9%)
Hepatitis C treatment
2 (1%)
Infection treatment
74 (37%)
Cardiovascular treatment
97 (49%)
Gastrointestinal treatment
34 (17%)
Pain treatment
50 (25%)
Urinary/prostate treatment
6 (3%)
Thyroid treatment
6 (3%)
Psychotropic treatment
66 (33%)
Sleep aid
7 (4%)
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Table 3. Enacted stigma item endorsement.
In the past year…

n (%)

People have treated me differently

61 (31%)

Family members have avoided me

23 (12%)

Family members have looked down on me

26 (13%)

Community/social workers have discriminated against me

22 (11%)

Healthcare workers have avoided touching me

17 (9%)

I have lost friends by telling them I have HIV

29 (15%)

People seem afraid of me

32 (16%)

People have physically backed away from me

35 (18%)

People who know I have HIV ignore my good points

35 (18%)

People don’t want me around their children

28 (14%)

I have been treated with hostility or coldness by strangers

27 (14%)

I have been ignored, excluded or avoided by people close to me

29 (15%)

I have been rejected by a potential sexual or romantic partner

45 (23%)

Someone acted as if I could not be trusted

25 (13%)

I was denied a place to live or lost a place to live

9 (5%)

I was treated poorly or made to feel inferior when receiving healthcare

18 (9%)

I was denied a job or lost a job

12 (6%)

Someone insulted or made fun of me

28 (14%)

My personal property was damaged or stolen

3 (2%)

I was physically assaulted or beaten

5 (3%)

Range # events endorsed in the past year

0 - 20

Mean # events endorsed in the past year

M: 2.6 (SD: 4.3)
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Table 4. Enacted stigma item selected as most impactful in the past year.
In the past year…

n (%)

People have treated me differently

20 (10%)

Family members have avoided me

4 (2%)

Family members have looked down on me

5 (3%)

Community/social workers have discriminated against me

0 (0%)

Healthcare workers have avoided touching me

3 (2%)

I have lost friends by telling them I have HIV

5 (3%)

People seem afraid of me

3 (2%)

People have physically backed away from me

2 (1%)

People who know I have HIV ignore my good points

3 (2%)

People don’t want me around their children

3 (2%)

I have been treated with hostility or coldness by strangers

3 (2%)

I have been ignored, excluded or avoided by people close to me

3 (2%)

I have been rejected by a potential sexual or romantic partner

17 (9%)

Someone acted as if I could not be trusted

3 (2%)

I was denied a place to live or lost a place to live

1 (1%)

I was treated poorly or made to feel inferior when receiving healthcare

4 (2%)

I was denied a job or lost a job

4 (2%)

Someone insulted or made fun of me

5 (3%)

My personal property was damaged or stolen

0 (0%)

I was physically assaulted or beaten

0 (0%)

Stress associated with most impactful event

M: 4.8 (SD: 3.3)

Composite stress score

M: 1.5 (SD: 2.0)

Frequency, past year, most impactful event
Almost everyday

18 (9%)

At least once a week

4 (2%)

A few times a month

8 (4%)

A few times this year

22 (11%)

About once this year

36 (18%)

Never (denied any events in the past year)

103 (52%)
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Table 5. Comparisons of sociodemographic characteristics between groups – participants who
endorsed enacted stigma in past year versus those who did not.
Characteristic
Age
Gender
Male
Female
Transgender
Race
African American/Black
White
Hispanic or Latino
Biracial or Multiracial
Other
Sexual Orientation
Homosexual/Same sex loving
Bisexual
Heterosexual/Straight
Education Level
Less than HS degree
HS degree or equivalent
More than HS degree
Employment
Working full time
Working part time
On disability
Unemployed
Student
Religion
Christian
Agnostic/Atheist
Spiritual but not religious
Other
Ever incarcerated
In the past month:
Unreliable transportation
Unstable housing
Food insufficiency
Mental Health Counselor
Substance Use Counselor
HIV Support Group
AA/NA Groups

Endorsed event
past year
(n= 96)
44.9 ± 12.5

Did not endorse
event past year
(n= 103)
46.5 ± 11.6

62
33
5

61
41
4

Between Group
Comparison
(F or χ2 p value)
.353
.429

.582
78
13
1
2
2

89
12
1
1
0

28
13
50

31
9
62

22
31
43

23
39
41

.462

.691

.791
13
7
38
34
3

13
12
41
35
2

71
2
12
11
52

77
0
8
17
48

.286

18
14
41
13
9
11
18

16
9
18
10
3
2
9

.547
.197
<.001*
.709
.187
.103
.634

.246
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Table 6. Comparisons of health and medical information between groups endorsing events of
enacted stigma in the past year.

Characteristic
Years since HIV Diagnosis
CESD score
CESD cognitive/affective
AUDIT
Internalized stigma
Visual analog med adherence
# Active medications
Most recent viral load
Most recent CD4 count
Quality of Life Measures
General health  “good”
Health not good  2 weeks
Health kept from activities
 2 weeks
Pain  2 weeks
Clinic attendance
Missed appointments
Attended all
Viral Load Status
Detectable (≥20)
Undetectable
CD4 cell count < 200

Endorsed event
past year (n= 96)
13.2 ± 8.8
18.3 ± 12.3
9.8 ± 6.7
4.7 ± 6.5
2.7 ± 1.2
86.2 ± 26.8
5.2 ± 3.5

Did not endorse
event past year
(n= 103)
13.7 ± 8.7
13.1 ± 10.2
6.8 ± 5.9
2.7 ± 4.0
2.1 ± 1.0
85.3 ± 26.0
6.0 ± 4.1

575.4 ± 278.4

575.4 ± 334.4

Between Group
Comparison
(F or χ2 p value)
.698
.002*
.001*
.008*
<.001*
.822
.113
.509
1.00

77 (80%)
37 (39%)
33 (34%)

86 (83%)
26 (25%)
17 (17%)

.311
.098
.021*

33 (34%)

23 (22%)

.067

42 (44%)
54 (56%)

49 (48%)
54 (52%)

30 (31%)
64 (67%)
7 (7%)

36 (35%)
63 (61%)
12 (12%)

.256

20 (19%)
12 (12%)
0 (0%)
41 (43%)
54 (52%)
24 (23%)
27 (26%)
4 (4%)
2 (2%)
32 (33%)
5 (5%)

.614
.184
.141
.428
.282
.016*
.714
.458
.359
.515
.289

.589

.515

Comorbid treatment
Pulmonary treatment
16 (17%)
Diabetes treatment
6 (6%)
Hepatitis C treatment
2 (2%)
Infection treatment
33 (34%)
Cardiovascular treatment
43 (45%)
Gastrointestinal treatment
10 (10%)
Pain treatment
23 (24%)
Urinary/prostate treatment
2 (2%)
Thyroid treatment
4 (4%)
Psychotropic treatment
34 (35%)
Sleep aid
2 (2%)
Note: Significant group differences denoted with a *.
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Table 7. Correlations between coping subscales (N=96).
1
2
3
4
5
1. Self
--Distraction
2. Active
.395
--**
3. Denial
.428
.435
--**
**
4. Substance
.368
.198
.411
--+
Use
**
**
5. Emotional
.350
.448
.411
.174
--+
Support
**
**
**
6. Instrumental
.363
.425
.434
.337
.735
Support
**
**
**
*
**
7. Behavioral
.263
.263
.592
.464
.301
Disengagement
*
*
**
**
*
8. Venting
.443
.419
.577
.295
.436
**
**
**
*
**
9. Positive
.415
.529
.387
.351
.422
Reframe
**
**
**
**
**
10. Planning
.489
.610
.426
.283
.616
**
**
**
*
**
11. Humor
.170
.218
.334
.358
.250
*
*
**
*
12. Acceptance
.501
.326
.269
.202
.363
**
*
*
*
**
13. Religion
.180
.163
.289
.086
.487
+
*
**
14. Self Blame
.343
.209
.329
.458
.248
*
*
*
**
*
Note: p<.001**; p<.05*; p<.10+

6

7

8

9

10

11

12

13

14

--.390
**
.540
**
.348
*
.540
**
.259
*
.276
*
.430
**
.373
**
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--.543
**
.399
**
.478
**
.328
*
.196
+

.287
*
.529
**

--.343
*
.473
**
.464
**
.410
**
.362
**
.481
**

--.662
**
.261
*
.345
*
.354
**
.235
*

--.354
**
.501
**
.445
**
.420
**

--.173

---

+

.253
*
.439
**

.427
**
.256
*

--.244
+

---

Table 8. Principal component analysis with varimax rotation of three-factor structure of the Brief
COPE (N= 96).

Subscale
Denial
Substance Use
Behavioral Disengagement
Venting
Humor
Self-Blame
Self-Distraction
Active Coping
Positive Reframing
Planning
Acceptance
Emotional Support
Instrumental Support
Religion

1
.579
.721
.751
.580
.653
.745
.259
.110
.232
.277
.075
.129
.326
.141
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2
.392
.319
.186
.307
.011
.115
.745
.738
.714
.659
.580
.389
.304
.107

3
.218
-.165
.196
.427
.246
.168
.022
.207
.205
.467
.328
.754
.669
.792

Table 9. Descriptive statistics of Brief COPE subscales in response to coping with most
impactful enacted stigma event in the past year (N = 96).
Brief COPE Subscale
M
SD
Denial Coping

3.97

2.09

Substance Use Coping

3.57

2.06

Behavioral Disengagement Coping

3.64

1.93

Venting Coping

4.16

2.16

Humor Coping

3.47

1.91

Self Blame Coping

4.03

2.00

Self Distraction Coping

4.58

2.14

Active Coping

4.70

2.17

Positive Reframe Coping

5.03

2.08

Planning Coping

4.55

2.06

Acceptance Coping

5.51

1.91

Emotional Support Coping

4.31

2.08

Instrumental Support Coping

4.11

2.02

Religion Coping

5.32

2.21

Maladaptive Coping composite score

3.80

1.48

Cognitive Adaptive Coping composite score

4.86

1.58

Supportive Coping composite score

4.58

1.76

Adaptive Cognitive + Supportive Coping composite score

4.75

1.49

Coping Factors

Note: Range of subscales is 2-8.
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Table 10. Correlations between sociodemographic and mental and physical health variables in full sample (N=199).
CESD
AUDIT
Internalized
Enacted
Clinic
Total #
VAS
VL>20
Stigma
Stigma
Attendance
medications
Adherence
Age
-.064
-.059
-.207*
-.025
-.178*
.462**
.143+
-.151*

CD4
<200
.061

Gender

.135+

-.089

.075

-.015

.151*

.168*

.027

-.095

.035

Sexual
minority
Education

-.036

.033

-.106

-.160*

-.218*

-.046

-.001

.174*

-.112

-.111

-.083

-.018

-.126+

.025

-.144*

-.036

.103

-.083

Working

-.232*

-.051

-.019

-.144*

.067

-.246**

-.064

.125

-.105

Stable
Housing
Food
insecurity
Years since
HIV diagnosis
CESD

.202*

.208*

.131+

.065

.075

-.038

-.040

.119

.044

.308**

.152*

.168*

.162*

.060

.006

-.055

.012

.051

-.089

-.087

-.210*

-.019

-.140

.354**

.076

-.095

.004

---

.201*

.433**

.359**

.035

.154*

-.123+

-.024

.067

AUDIT

---

---

.209*

.133

.074

.029

-.062

.183*

.048

Internalized
HIV stigma
Enacted HIV
Stigma
Clinic
Attendance
Total #
medications
VAS
Adherence
Viral load>20

---

---

---

.372**

-.026

-.142*

-.127+

.078

.107

---

---

---

---

-.001

-.083

-.130+

-.089

.002

---

---

---

---

---

-.027

-.101

.101

.023

---

---

---

---

---

---

-.032

-.055

.126*

---

---

---

---

---

---

---

-.321**

-.024

---

---

---

---

---

---

---

---

.246*

Note: p<.001**; p<.05*; p<.10+
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Table 11. Correlations between sociodemographic variables and outcome variables in path model (N=96).
Stress
Maladaptive
Adaptive
Clinic
Total #
Med
Viral Load
Coping
Coping
Attendance medications Adherence
Status
(VAS>85%)
(VL>20)
Age
-.095
-.067
-.043
-.163
.443**
.049
-.037
Gender
.024
.055
.038
.063
.253*
.030
-.223
Racial minority
.107
.099
.111
-.011
-.076
-.076
-.056
Sexual minority
-.049
-.115
-.069
-.179+
-.129
.024
.263*
Education
-.019
.017
-.037
.042
-.120
-.010
.075
Working
-.209*
-.277*
-.098
-.015
-.323*
.009
.161
Stable Housing
.022
.169
.161
.103
-.038
.076
.255*
Years since
-.068
-.142
.001
-.102
.381**
-.029
-.076
HIV diagnosis
CESD
.395**
.429**
.172
.001
.214*
.009
-.009
AUDIT
.092
.282*
.166
.144
.020
-.091
.175+
Internalized
.366**
.473**
.242*
-.036
.002
-.094
.047
HIV stigma
Enacted HIV
.368**
.414**
.192+
.023
-.058
-.111
-.106
Stigma
Stress
--------------Maladaptive
.311**
------------Coping
Adaptive
.246*
.619**
----------Coping
Clinic
.062
-.118
-.080
--------Attendance
Total #
.094
.149
.037
-.148
------medications
Med
-.024
-.140
-.097
-.020
-.028
----adherence
Viral load>20
.071
-.093
-.096
-.050
-.044
-.300*
--CD4<200
.140
.063
-.013
-.168
.272*
.058
.240*
Note: p<.001**; p<.05*; p<.10+
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CD4
(<200)
.140
.044
-.004
-.096
-.228*
-.157
.121
.105
.106
.085
.226*
.072
-----------------

Table 12. Associations between model mechanisms and HIV-related health outcomes.
Stress

Maladaptive
Coping
B(SE)=0.55
(0.11)
=0.45
p<.001
B(SE)=0.13
(0.05)
=0.27
p=.01
---

Adaptive
Coping
B(SE)=0.29
(0.12)
=0.24
p=.02
B(SE)=0.12
(0.05)
=0.25
p=.02
---

Number
Clinic
VAS<85%
Viral Load
CD4<200
Meds
Attendance
Status
Internalized B(SE)=0.92
B(SE) =0.12 OR=0.96
OR=0.84
OR=1.00
OR=2.15
HIV Stigma
(0.26)
(0.27)
(0.68-1.31)
(0.57-1.23)
(0.66-1.54)
(1.04-4.46)
p=.72
p=.36
p=.98
p=.04
=0.35
=0.04
p=.001
p=.66
Stress
--B(SE)=0.09 OR=0.69
OR=0.98
OR=1.09
OR=1.19
(0.10)
(0.91-1.18)
(0.85-1.14)
(0.93-1.28)
(0.92-1.54)
p=.56
p=.83
p=.31
p=.20
=0.09
p=.36
Maladaptive --B(SE)=0.33 OR=0.85
OR=0.81
OR=0.83
OR=1.21
Coping
(0.23)
(0.64-1.13)
(0.59-1.11)
(0.56-1.22)
(0.73-1.99)
p=.25
p=.18
p=.34
p=.46
=0.14
p=.14
Adaptive
------B(SE)=0.04 OR=0.90
OR=0.86
OR=0.82
OR=0.94
Coping
(0.21)
(0.68-1.18)
(0.63-1.18)
(0.58-1.17)
(0.55-1.60)
p=.44
p=.35
p=.27
p=.83
=0.02
p=.87
Note: standardized betas and regression coefficients with standard errors presented for linear regressions. Odds ratios and
confidence intervals presented for logistic regressions.
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Table 13. Regression analyses among study variables predicting health outcome (VAS<85%).
Consequent
M1 (Stress)
M2 (Maladaptive Coping)
Antecedent
B
SE
p
B
SE
p
X (Internalized
a
.917
.263
<.001
b
.571
.114
<.001
c’
Stigma)
M1
------------d1
M2
------------d2
V (Adaptive
------------e1
Coping)
M1 x V
------------e2
Constant
iM1
2.651
0.840
.002
iM2
2.407
0.364
<.001
iY
R2=.413
R2=.282
F(2, 83)=8.509, p<.001
F(2, 83)=16.310, p<.001
Note: Employment status was included as covariate.
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Y (VAS<85%)
B
SE
p
-.175
.254
.492
.119
-.003
.176

.273
.673
.477

.663
.996
.713

-.018
1.245

.051
2.218

.729
.575

Figure 1. Conceptual model adapted for current study to investigate the relationships between
HIV stigma and HIV health outcome mediated by perceived stress and maladaptive coping
strategies, with potential buffering effects of adaptive coping resources.
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Figure 2. Conceptual model tested in current study showing significant association between
internalized HIV stigma and stress related to most impactful enacted stigma event in the past
year, as well as maladaptive coping approaches in response to most impactful enacted stigma
event. Employment status was included as a covariate in analysis.
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